Jia Jenny Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn:
“Early phase oncology trials isn’t just about the next molecule. It’s about whether our systems can keep up with the science.
On 27 March, NSW Early Clinical Trials Alliance (NECTA) is bringing together international and national leaders in precision oncology.
Highlights include:
- Project Optimus in practice – Timothy Yap.
- The agnostic approach to precision oncology – Cook, Natalie.
- Drug development insights from China – Yu Xiang Ma.
- T-cell engagers in solid tumors – Ben Tran.
- Patient-reported outcomes in early phase trials – Aaron Hansen.
- NECTA Research highlights including financial/time toxicity, balancing wellbeing in phase 1 units, bench to bedside discoveries and updates on Bayesian designs Hao-Wen Sim, Udit Nindra, Rachel Galimidi, Anthony Joshua.
I’ll be presenting the final PANNA-COTA analysis: what happens when liquid biopsy, a real-time multidisciplinary tumor board, and a statewide phase I network are deliberately integrated.
Innovation doesn’t scale itself.
Systems determine impact.
If you’re working in early phase drug development, biomarker strategy, or trial navigation, join us.
– 27th March 2026 9-5pm.
– Garvan Auditorium and online, 384 Victoria St, Darlinghurst, NSW 2010 AU.
– Register here.”
Other articles about Liquid Biopsy on OncoDaily.
